Vygon, an Ecouen, France-based specialist single-use medical devices group, acquired Perouse Medical, a French manufacturer of medical devices.
The financial terms of the agreement were not disclosed.
Perouse Medical will be the cardiovascular and long-term vascular access specialist within the Vygon group. The adult long-term vascular access market, which is estimated to be worth €1.1 billion ($1.2 billion) and the synergies between Perouse and Vygon’s various product ranges will allow Vygon to expand its portfolio of available products and strengthen its commercial presence in France and abroad. The operation also aims to develop expertise on new single-use health product families, with a focus on interventional cardiology and the treatment of cardiovascular diseases.
Thomas Walter, the current deputy director general of Perouse Medical, will be responsible for the general management of the company and will join the Vygon Group executive committee.
Established in 1984, Perouse Medical designs, manufactures and markets cardiovascular medical devices (stents, vascular grafts and patches, radial compression and inflation systems, hemostatic valves, angiographic syringes, as well as fluid management consumables for contrast media injectors for scanners and MRI, etc.) and long-term vascular access devices (implantable ports, PICCs, Huber needles, catheter maintenance dressings, etc.).
The company generated a turnover of €28.2m ($31.4m) in 2014. It has a presence in 90 countries and a network of 200 distributors.
Perouse Medical employs 336 people in its French offices in the Oise region (Ivry-le-Temple) and in the Greater Lyon area of the Rhône-Alpes region (Irigny).
A family company founded in 1962, Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals in hospital and for private and independent practitioners.
The company distributes over 200 million products a year in more than 100 countries through its network of 25 subsidiaries and 79 distributors. Vygon products display the CE and/or FDA mark and are manufactured in the group’s eight factories in Europe, the USA and Colombia.
It employs 1,800 staff worldwide and in 2014 had a turnover of €263m ($285m).
FinSMEs
06/07/2015